Zentalis Pharmaceuticals, Inc.
ZNTLNasdaqHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — | — |
| Operating income | −$152.8M | −$191.2M | −$299.5M | −$227.3M | −$216.5M | −$118.8M |
| Net income | −$137.1M | −$165.8M | −$292.2M | −$236.8M | −$158.7M | −$117.8M |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M | $365.6M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M | $32.2M |
| Equity | $216.2M | $337.2M | $437.3M | $433.8M | $364.5M | $333.4M |
| EPS (diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 | $-4.19 |
| Shares out. | 71.8M | 71.0M | 59.4M | 45.6M | 41.0M | 41.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −63.4%
- Return on assets
- −47.4%
- Return on capital (ROCE)
- −60.5%
- Liabilities / assets
- 25.2%
- Debt / equity
- 0.34×
- Book value / share
- $3.01
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -8.96distress
- Accruals / assets
- −4.1%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 2 good- Altman Z″ in the distress zone
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Squadron Capital Management LlcPassive (13G)Mar 3, 2026
- Walters GroupPassive (13G)Jan 5, 2026
- Matrix Capital Management Company, LpActivist (13D)Jan 2, 2026
- 5am Opportunities Ii (Gp), LlcPassive (13G)Dec 30, 2025
- Barclays PlcPassive (13G)Nov 12, 2025
- Millennium Management LlcPassive (13G)Oct 14, 2025
- Blackrock, Inc.Passive (13G)Jul 16, 2025
- Eventide Asset Management, LlcPassive (13G)May 14, 2025
- Walters William TPassive (13G)Jan 31, 2025
- Vanguard Group IncPassive (13G)Jan 31, 2025
- Fmr LlcPassive (13G)Dec 6, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.9M | 5.5 | -10.3% |
| Apr 30, 2026 | 5.5M | 3.9 | +5.5% |
| Apr 15, 2026 | 5.2M | 1.0 | +22.1% |
| Mar 31, 2026 | 4.3M | 8.5 | +2.1% |
| Mar 13, 2026 | 4.2M | 5.4 | +10.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 27, 2026
- Regulation FD disclosure · Other material eventMay 21, 2026
- Results of operations · Regulation FD disclosureMay 12, 2026
- Regulation FD disclosure · Other material eventMay 5, 2026
- Regulation FD disclosureApr 17, 2026
- Regulation FD disclosure · Other material eventApr 9, 2026
- Results of operationsMar 26, 2026
- Regulation FD disclosure · Other material eventJan 9, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.